Although the prospect of long-term leukemia-free survival (LFS) after treatment for adult acute lymphoblastic leukemia (ALL) is widely accepted, few studies have reported long-term survival data. Three hundred and seventy-eight ALL patients, referred to our hospital from 1978 to 1999, were reviewed for long-term follow-up data. The analysis included data on 351 patients treated by standard chemotherapy according to 11 different successive and/or concomitant regimens. Complete remission (CR) was achieved in 299 patients (79%). Initial performance status, LDH level, immunophenotype, age, and risk group (defined according to Hoelzer's criteria) at diagnosis were of significant prognostic value for CR achievement. Median leukemia-free survival (LFS) was 14 months with a 3-year, a 5-year, and an 8-year LFS at 30%, 26%, and 24%, respectively. LFS was better in T cell lineage ALL than in B cell lineage ALL (P ‫؍‬ 0.05). Younger age was also a favorable prognostic factor for LFS (P ‫؍‬ 0.001). Philadelphia-positive (Ph+) ALL displayed a poor outcome since median LFS was 7 months with only 13% of survival at 3 years. Median overall survival (OS) of the entire cohort was 18 months with a 3-year, a 5-year, and an 8-year OS at 32%, 24%, and 22% respectively. Favorable prognostic factors for OS were younger age (P Ͻ 0.0001), and T cell lineage ALL (P ‫؍‬ 0.001). Among non-T cell lineage ALL, standard-risk ALL confirmed a significant better outcome than high-risk ALL (P ‫؍‬ 0.0003). It was apparent from this analysis that hazard rates for death and relapse were greatest in the first year, decreased substantially between years 1 and 2, then decrease further between years 2 and 3. Rates of death and relapse were quite low after 3-4 years. All patients relapsing after 3 years of CR were B or non-B non-T cell lineage ALL. Long-term survivors (LTS), defined as survival in CR у3 years, represented 23% of evaluable patients. Eighty-three patients remain alive in initial CR at Ͼ3 years, while only three were LTS after a second CR. Overall, no significant improvement was shown in terms of CR achievement and survival duration over the years. However, regarding survival, a significant improvement was demonstrated in T cell lineage ALL (P ‫؍‬ 0.03). Furthermore, patients (aged less than 50 years) transplanted while in first CR did significantly better than those receiving only chemotherapy as post-remission therapy (P Ͻ 0.0001). The 3-year OS, after allogeneic transplantation in first CR, was 74% in T cell lineage ALL, while it was less than 50% in B cell lineage ALL. This single center study on a large cohort of ALL patients reflects the degree to which ALL treatment remains unsuccessful in adults. Only T cell lineage ALL outcomes have improved over the years. The results suggest a time (3 years) at which it becomes reasonable to speak of potential cure, provided the patient is in CR. Leukemia (2001) 15, 1811-1822.
Introduction
Over the past two decades, great progress has been made in the treatment of childhood acute lymphoblastic leukemia (ALL). Greater understanding of the optimal use of a variety of antineoplastic agents, as well as improvements in the quality and availability of broad-spectrum antibacterial antibiotics, antifungal agents, and platelet transfusions, have resulted in gradual improvements in complete remission (CR) and longterm disease-free survival rates. 1 Similarly to treatments in children, risk-adapted strategies are now being applied to adults with ALL to improve survival. However, the same or similar treatments applied in adults have not yielded the same favorable results that have been achieved in childhood ALL. The different response of children and adults is still poorly understood, but can be attributed in part to the higher frequency of adverse genetic abnormalities in the leukemic lymphoblasts of adults. Although few substantial improvements have been observed in the overall cure rate, significant changes have been reported in some ALL subgroups. Recent studies in adults have shown that aggressive therapy may improve treatment results and the possibility of long-term leukemia-free survival (LFS) for adult ALL patients after management with chemotherapy alone or chemotherapy plus stem cell transplantation is now widely accepted. LFS rates at 3 or more years in large series range from 13% to 44%. [2] [3] [4] [5] [6] [7] [8] [9] This wide variation is most probably not only due to variations in therapeutic regimens and the frequency of bone marrow transplantation (BMT), but also to different inclusion and exclusion criteria. Many questions, regarding treatment strategies in adult ALL, are still opened and comprise as follows: (1) the intensification of induction therapy in order to improve remission quality; (2) the justification to treat according to immunologically or cytogenetically defined subtypes; (3) the indications for allogeneic or autologous transplantations.
Although there are many publications that describe the outcome of chemotherapy trials in ALL, few of them include the results of long-term follow-up beyond 8 or even 5 years after study entry. Furthermore, most of the publications report results of clinical trials and deal with selected patient populations. The purpose of the current retrospective single center study was to give some indications on the improvement of outcome which has been achieved during a long period of time, to determine the number of long-term survivors, identify factors that predicted for long-term survivors (LTS), and identify other factors that might impact on the outcome and therefore on the quality of life of these individuals. To address these issues, we have reviewed data on 378 previously untreated patients with a pathologic diagnosis of ALL admitted to our department over a 21-year period (from June 1978 to November 1999). These data provide important insights into the prospects for the long-term survival of adult patients with ALL. These findings should prove useful both in clinical practice and in the design of future studies. It might better reflect the outcome for a less-selected population of patients.
Patients and methods

Patients
From June 1978 to November 1999, a total of 378 consecutive adult patients have been admitted to the Edouard Herriot Hospital (Lyon, France) for newly diagnosed ALL. We retrospectively reviewed the clinical and biological characteristics of those patients at presentation, treatment variables, as well as outcome from the first day of admission. Only two reports were excluded from the present study regarding treatment outcome because of lack of adequate data. Diagnosis of ALL was established on the basis of bone marrow aspirate. ALL were classified according to the morphological French-AmericanBritish (FAB) criteria, 10 completed by cytochemical and immunological analyses. Based on the pattern of reactivity, lymphoblasts were classified as T (CD7
. The level of differentiation into early pre-B stage was evaluated by the presence of the CD10 and CD20 antigens. 11 Myeloid-antigen-positive (My + ) ALL was defined as co-expression of lymphoid markers and at least two myeloid-lineage-associated antigen (CD13/CD14/ CD15/CD33) on у20% of the lymphoblasts. Cytogenetic analysis, routinely performed starting from the late 1980s, was performed in 294 patients (77%) on bone marrow and/or peripheral blood cells before initiation of therapy, using short unstimulated cultures and RHG banding. Karyotypes were analyzed according to the International System for Human Cytogenetic Nomenclature.
12 Two different classifications were used. In the first classification, patients were grouped according to the presence or absence of normal metaphases (NN/AN/AA). Twenty normal metaphases were required to classify a karyotype in the normal group. In the second chromosome grouping, karyotypes were classified according to ploidy groups or structural (recurrent) abnormalities. Molecular characterization of BCR/ABL, E2A-PBX1, HRX-AF4 rearrangements at diagnosis were routinely performed since 1992. In this study, only 77 patients were studied at diagnosis using a reverse transcription polymerase chain reaction (RT-PCR). Chromosomal fluorescence in situ hybridization (FISH) was occasionally used since 1994 with labeled probes for mBCR or MBCR/ABL translocation. Central nervous system (CNS) leukemia was diagnosed on the basis of cranial nerve palsies with or without leukemic blasts in the cerebrospinal fluid, or when at least five mononuclear cells per microliter of cerebrospinal fluid with blasts were present in a cytospin preparation. 13 All non-T cell lineage ALL patients were classified as being at 'standard or higher risk' of relapse, based on Hoelzer's criteria. 5 High-risk ALL patients were defined as having at least one of the following factors: age Ͼ35 years, WBC counts Ͼ30 × 10 9 /l, and Philadelphia-positive (Ph+) or 11q23 chromosomal abnormality.
It should be noted that the diagnostic criteria for ALL changed during those 21 years. Hence, it is possible that some patients diagnosed during the late 1970s would not be considered to have ALL according to current criteria. Conversely, some patients who would have been diagnosed with ALL by today's criteria may have been excluded from our study. Furthermore, because of the lack of adequate biological analysis, Ph+ ALL have been definitively underestimated before 1992.
Treatment
Five patients died early before any chemotherapy could be given. Ten patients were misdiagnosed initially with acute non-lymphoblastic leukemia (ANLL) and treated on an ANLL protocol. Ten patients received palliative therapy, consisting of corticosteroids or low-dose chemotherapy, because of advanced age, and/or poor medical condition. Three hundred and fifty-one patients received ALL standard induction chemotherapy. Patients were considered to have had standard induction therapy if they received a regimen containing a corticosteroid, vincristine, ± cyclophosphamide, ± anthracycline, ± bleomycine combination. Three hundred and fortythree of those 351 patients were treated according to 11 successive and/or concomitant treatment protocols officially used in our institution, 4, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] while eight patients received nonofficial or occasionally used regimens. Marrow response status was determined by bone marrow aspirates at about day 28 of induction chemotherapy. Patients who did not achieve CR in one course of chemotherapy as evaluated by the persistence of blast in day 28 bone marrow aspirate, received salvage therapy according to the protocol design in which they were included. Similarly, patients with CR after induction or salvage were given consolidation chemotherapy or transplantation. Details of the specific protocols have been provided previously. 4, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Schedules of protocol trials are summarized in Figure 1 . Adjustments in the post-remission chemotherapy program were made to the dose or timing of consolidation therapy only under exceptional circumstances. Doses and timing of maintenance cycles were adjusted frequently to prevent unacceptable neutropenia or thrombopenia. As postremission therapy, 79 patients received early bone marrow or peripheral stem cell transplantation (SCT). Sixty-one patients underwent allogeneic bone marrow transplant (BMT), while 18 patients received autologous SCT. The conditioning regimen for allogeneic or autologous SCT consisted of cyclophosphamide and total body irradiation (TBI). Since 1994, conditioning regimen also comprised etoposide preceding cyclophosphamide and TBI administration in case of Ph+ ALL. Prophylaxis of graft-versus-host disease (GVHD) following allogeneic transplant consisted of either cyclosporine A alone, or cyclosporine A in combination with methotrexate. At time of relapse or in refractory ALL, miscellaneous treatments have been used according to patient's age and ongoing regimens. Thirty-three patients were allografted in second CR or with progressive disease, and nine patients were autografted in second CR. Since 1993, matched BMT from unrelated donors have been proposed in the absence of an HLA-identical sibling. Conditioning regimen included anti-lymphocyte globulins combined with the regular combination of cyclophosphamide and TBI. Eight patients received allogeneic transplant from an unrelated HLA-identical donor. Five patients, who received a first allogeneic BMT as consolidation therapy during the first-line treatment, underwent another allogeneic transplantation in second-line therapy. In the case of second SCT, conditioning regimen included busulfan followed by cyclophosphamide. Schedules of standard protocol regimens used over the 1978-1987 and 1987-1999 periods. Protocols running between 1978 and 1987 were used for all ALL patients. They, therefore, involved patients officially included into the successive trials and patients who did not meet inclusion criteria but who were treated according to those regimens. Among protocols used for the 1987-1999 period, LMBA-95 was designed for L3 ALL only, and LALAsa-92 and LALAsa-97 for ALL patients Ͼ55 years. Patients of all ages were treated according to the LALA-87 regimen, while only patients aged less than 60 were treated according to LALA-91 and LALA-94 regimens. All other regimens involved patients officially included in the successive trials and patients who did not meet inclusion criteria but who were treated according to those regimens. Adria, adriamycin; Allo, allogeneic BMT; AraC, cytarabine; AraCVmb, cyclophosphamide + teniposide + bleomycin + cytarabine + methylprednisolone; Aspa, asparaginase; Auto, autologous SCT; Bleo, bleomycin; Consolidation 1, vincristine + adriamycin + cyclophosphamide + methotrexate + prednisone; Consolidation 2, cytarabine + etoposide; COP, cyclophosphamide + vincristine + prednisone; COPADEM, vincristine + methotrexate + cyclophosphamide + adriamycin + prednisone; CPM, cyclophosphamide; CYVE, cytarabine + high-dose cytarabine + etoposide; DNR, daunorubicin; HAM, high-dose cytarabine + mitoxantrone; Ida, idarubicin; IFN, interferon-␣; Ifo, ifosfamide; 6MP, 6-mercaptopurine; MTX, methotrexate; PDN, prednisone; R, randomization; R*, genetic randomization; RBZ, rubidazone; 6TG, 6-thioguanine; VAD, adriamycin + vincristine + dexamethasone; VCR, vincristine; VDS, vindesine.
Leukemia
The current analyses were based on all registered patients, whereas the earlier reports were limited to eligible patients. Patients' data have been updated for the current study. The results presented here are based on data available as of November 2000.
Statistical analysis
CR was defined according to the CALGB criteria as less than 5% blasts in bone marrow aspirates with evidence of maturation of cell lines and restoration of peripheral blood counts. 24 Patients failing induction therapy were categorized as failures and divided into (1) death during induction (death occurred while the patient was receiving induction therapy); and (2) resistant (the patient survived induction, but resistant leukemia redeveloped). Hematological relapse was considered when more than 5% blasts were seen in two bone marrow aspirates obtained at 15-day interval. 24 Overall survival (OS) was calculated from the date of diagnosis to the date of death (failure) or the date the patient was last known to be alive (censored). Kaplan-Meier curves were then generated based on the updated data and were compared for statistical significance by the log rank test. 25 End points for LFS duration were date of relapse (failure), date of death during an intensification course (failure), date of other deaths in CR (censored), or date last alive without evidence of relapse (censored).
A number of practical problems arose in determining the status of some individual patients still at risk, represented by the 'tick' marks on the curves. Indeed, an important issue in analyzing long-term LFS was the question of 'uninformative censoring'. Patients who were at risk of failure may be 'lost to follow-up' (although they are known to have died), but without the investigator's knowledge of when or whether relapse occurred. Early in a study, deaths were very likely leukemia-related, but later deaths were more difficult to define without specific bone marrow data. In a sense, we were performing an analysis of competing risks. Estimates of cure were affected by whether cases of 'death without documented relapse' were considered to be treatment failures or censored. Additionally, analyses of study-specific LFS did not capture the benefit of effective salvage therapy after relapse. This was especially important for transplantation as second-line therapy. Also, the impact of lingering or late toxicity was not captured. Survival was the ultimate test of patient benefit. Then, we focused on long-term survivors (LTS), defined as survival of 3 years or more after study entry. Specifically, patients who continued in complete remission for at least 3 years were considered 'cured' because relapse was rare after that time point.
In order to assess the best treatment strategy over the years, treatment outcome was studied after patients were separated on to different categories. Analysis was done first for the whole population, and subsequently two analyses were performed according to year of admission and treatment only for patients receiving standard therapy. First, two time periods (analysis 1) were chosen (1978-1987, 119 patients; and 1987-1999 , 232 patients) in order to assess potential improvements according to the period of enrolment among all patients receiving standard therapy. The cut-off point represented the beginning of the LALA-87 protocol 4 characterized by an increased allocation on to phase III clinical trials and more systematic recourses to allogeneic BMT or autologous SCT as post-remission therapy. Second, five time periods (analysis 2) were arbitrarily chosen: 1978-1983, 41 patients (L10, 20 ACVBP, 22 
Results
Patient characteristics
Main characteristics are summarized in Table 1 . The entire cohort was composed of 378 patients (231 males and 147 females, sex ratio 1.57) with a median age of 35 years (range, 14-89 years). Morphological FAB classification was available in 349 cases: 183 patients (52%) were classified as L1, 102 (29%) as L2, 23 (7%) as L3, and 41 (12%) as undifferentiated ALL. By immunophenotype, 251 of the 361 studied patients (70%) were classified as B cell lineage ALL, 88 (24%) as Tlineage ALL, and 22 (6%) as non-T non-B cell ALL. By cytogenetic classification, 247 of the 294 patients, in whom karotypic data were available, could be classified for the absence or presence of normal metaphases. Eighty-two patients (33%) were classified as NN, 127 (51%) as AN, and 38 (16%) as AA. Fifty-one patients had Ph-positive ALL. Twelve patients presented with 11q23 chromosomal abnormality. Nonrandom hyperdiploidy Ͼ50 chromosomes was found in 28 cases. Among the 290 non-T cell lineage ALL with enough available data, 90 patients (31%) were classified as standardrisk ALL, while 200 (69%) displayed high-risk features.
Response to therapy
Three hundred and fifty-one of the 376 evaluable patients (93%) received a standard induction treatment. Abstention of chemotherapy or palliative therapy was more frequent in elderly patients (12 cases) than in younger patients (three cases). Ten initially misdiagnosed patients were treated on an ANLL protocol. Overall, induction treatments resulted in CR in 299 patients (79%) following administration of one (265 patients, 70%) or two (34 patients, 9%) induction courses, as did 83% of the 351 patients receiving standard therapy (74% CR after one course and 9% after two courses). Seventy-seven patients had refractory ALL (33 patients) or died (44 patients) during induction. The median LFS was 14 months (95% CI, 12-17
Figure 2
Kaplan-Meier plots of LFS in ALL patients (299 patients) seen in our institution over a 21-year period.
Leukemia months). Thirty percent of the patients remained continuously free of leukemia for more than 3 years, 26% for more than 5 years, and 24% for more than 8 years (Figure 2 ). Within the 21-year period, 190 of the patients who achieved CR (63%) had relapses of their leukemia. Relapse was by far the major reason for failure after attainment of complete remission. With the exception of the 30 patients who died while in CR, the remaining 183 deaths were related to recurrent leukemia. Most of the 190 relapses occurred by year 3 and nearly all the rest occurred by year 5, with rare relapses observed as late as 7.8 years after entry into the study and none thereafter. The 5-year LFS rate for patients Ͻ50 years who received only chemotherapy was 22%. The results with transplantation appeared better (P Ͻ 0.0001). There was, however, no statistical difference when comparing autologous transplantation and chemotherapy. The 5-year LFS rate rose to 26% with autologous transplantation and to 52% with allogeneic BMT (Figure 3) . Median survival duration for the whole population of patients was 18 months (95% CI, 14-21 months) with a 3-year OS, a 5-year OS and an 8-year OS of 32%, 24%, and 22%, respectively. Survival of transplanted patients, according to time and status at transplantation, are given in Table 2 . The 3-year OS was 74% in T cell lineage ALL allografted in first CR, while it was less than 50% in B cell lineage ALL.
Results according to the period of diagnosis and treatment
Analysis of patient outcome according to date of diagnosis and treatment globally indicated no statistically significant improvement in terms of CR achievement and survival duration over the years (Tables 3 and 4) . However, when considering separately B and T cell lineage ALL, it appears that a significant improvement was observed in T cell lineage ALL, while prognosis of B cell lineage ALL remained quite similar over the years. Outcome of mature B cell ALL (L3 ALL) did not improve significantly over the years. However, few patients were treated according to regimens specifically
Figure 3
Kaplan-Meier plots of LFS in ALL patients undergoing allogeneic (61 patients) or autologous (18 patients) stem cell transplantation as post-CR1 therapy. (Figure 4 ). A statistical difference was also observed in terms of LFS when considering analysis 2 (patients with non-L3 ALL, aged less than 60 years, and treated by standard chemotherapy) (P = 0.007) ( 
Long-term survivors
Failure rate after induction chemotherapy was higher for patients in second-line (only 47% of second CR) than for those in first-line therapy. However, in both cases (first and second CR) the failure rate fell to a relatively low level after 3 years in CR. This led us to consider patients as being in the potentially 'cured' cohort once they had been in first or second CR 
Figure 4
Kaplan-Meier plots of LFS in T-lineage ALL patients, receiving standard induction therapy, according to two periods of time (analysis 1).
Leukemia for у3 years. A total of 83 patients in first CR and three patients in second CR met this criterion. These 86 patients represented 23% of the 376 evaluable patients treated for newly diagnosed ALL between 1978 and 1999. Follow-up of the potentially 'cured' cohort indicated that 11 patients (13%) had recurrence of ALL at a median of 0.9 year (range, 0-4.8 years) after entering the cohort. Another four patients (5%) died in CR at a median of 1 year (range, 0.3-3.7 years) after entering the cohort. All those patients had B or non-B non-T cell lineage ALL. No patient with T cell lineage ALL relapsed or died in CR after 3 years in first or second CR. Thus, 71 patients (82% of this cohort) remain alive in CR. The median follow-up after entry into the cohort was 8.6 years (range, 0.1-16.8 years) for this group. Considering all 376 evaluable patients in the database, 17% have been in CR for Ͼ5 years and 10% for Ͼ8 years (although not all patients have been observed for these lengths of time).
Treatment regimens changed over the 21 years covered by this analysis. Patients treated between 1987 and 1999 were not significantly more likely to be LTS than those treated between 1978 and 1987. It is important to note that even if all 10 living patients with insufficient follow-up to qualify them as LTS were eventually to become LTS, the P value would still not be significant.
There were other categories of 'LTS'. A first group was composed of those whose first remission was Ͻ3 years in duration, but who survived for у3 years (22 patients). A small number Leukemia of patients never achieved a CR after a first-line therapy, but were alive beyond 3 years after achieving or not a CR with a second-line treatment (two patients). An additional 10 patients are alive in first CR at Ͻ3 years and could become LTS, but are classified as non-LTS for the purpose of this analysis.
Prognostic factors
Several clinical, biological and treatment-related data were analyzed for prognostic significance for achievement of CR, LFS and OS. In univariate analysis, the CR rate was significantly affected by WHO performance status (P Ͻ 0.0001), LDH level (P = 0.02), immunophenotype (P = 0.004), age (P Ͻ 0.0001), risk group at diagnosis (P = 0.0005) and kinetics of BM leukemic cell disappearance (P Ͻ 0.0001) ( Table 5) . A logistic regression analysis was performed with the following predictors: age, initial WHO performance status, LDH level, immunophenotype. In this model, the significant predictors of CR achievement were WHO performance status (P Ͻ 0.0001; relative risk (RR), 0.46; confidence interval (CI) (RR), 0.32-0.65) and LDH level (P = 0.02; RR, 1.0; CI (RR), 0.99-1.00).
LFS and OS, according to main characteristics, were summarized in Table 6 . In univariate analysis, LFS was positively influenced by younger age (P = 0.001) (Figure 5) , the presence of a T-lineage immunophenotype (P = 0.05) (Figure 6 ), and a post-remission treatment by transplantation (P Ͻ 0.0001) when considering patients aged Ͻ50 years. Age at presentation (P Ͻ 0.01; RR, 1.93; CI (RR), 1.34-2.79) remained as a prognostic factor for LFS in multivariate analysis.
In univariate analysis, overall survival was negatively influenced by non-T lineage immunophenotype (P = 0.001), age (P Ͻ 0.0001), and the presence of high-risk factors for non-T cell lineage ALL (P = 0.0003) ( Table 6 ). In multivariate analysis taking into account age, immunophenotype and period of therapy, only age (P Ͻ 0.01; RR, 1.02; CI (RR), 1.01-1.03) remained of prognostic value for OS.
Discussion
Although the concept of cure in adult ALL is now widely accepted, few studies with prolonged follow-up have been reported. According to most reports, 68 to 88% of adult ALL patients achieve CR after intensive chemotherapy. 2, 3, 7, [27] [28] [29] Median CR duration ranged from 20 to 32 months with longterm survival at about 30%. However, effects of selection on treatment results have been highlighted by most studies. Few population-based analyses were reported due to lack of registries in adult ALL. 30 Our present study, which provides prolonged follow-up confirms that cure of ALL is not infrequent. Compared to randomized trials, our historical single center study on a large population of patients decreases selection biases and reflects more accurately the prognosis of adult ALL. The higher CR rate obtained in our standard-treated ALL, when compared to CR rate obtained in our entire cohort, tends to confirm the non-relevant data given in most trials. Furthermore, median LFS was shorter in our less selected ALL population than that in most trials. On the other hand, the percentage of LTS was similar to that observed in most trials. This could probably be explained by a long survival in the same type of patients, as well as in a selected rather than in a non-selected ALL population.
A major focus of clinical research remains the identification of predictive factors for outcome. The hope is that therapy can eventually be tailored to the specific characteristics of individual patients and their disease. Because the registry described herein was initiated as long ago as 1978, many disease characteristics of current interest were not studied in all patients mainly because of missing clinical data in patient's record or because of technical problems in performing biological analysis. Among the factors universally available for study, two were closely associated with survival: age and immunophenotype. Younger age and T cell lineage ALL were related to better prognosis. Previous findings suggest that the major reason for the poorer outcome in elderly ALL patients is that they tend to have a different form of the disease than younger patients, with an increased incidence of unfavorable cytogenetics (data not shown). 31 The better prognostic value of T cell lineage ALL over B cell lineage ALL after 1987 (while B cell lineage ALL had a better prognosis before 1987) definitively illustrates the need for adapted therapy with regard to immunophenotype. The WBC count at diagnosis has consistently been found to be associated with outcome. 29 WBC is simply a reflection of tumor burden suggesting that with greater tumor burden there is an increased chance for the emergence of a drug-resistant clone. It is also just as possible that the link between a high WBC and chemotherapy resistance reflects an inability of the leukemic cell to arrest and undergo apoptosis in response to chemotherapy, or any of a number of other abnormalities. Actually, WBC count did not appear as a major prognostic factor in our study. When taking into account all ALL subtypes, its predictive value was probably masked by the lack of prognostic value for hyperleukocytosis in T cell lineage ALL. 4, 7 On the other hand, a WBC count between 25 and 30 × 10 9 /l represents an appropriate cut-off point for stratifying the risk in B cell lineage ALL. 4 ,7,27,32 
Figure 5
Kaplan-Meier plots of LFS in ALL patients according to age.
The predictive value of Hoelzer's criteria was confirmed in our study, despite an inaccurate determination of Ph+ ALL and ALL with 11q23 chromosomal abnormality until 1992 related to the lack of a systematic molecular analysis. Cytogenetic data from very few large series of adult ALL patients have been reported, 33 and essentially no long-term follow-up data are available. This 21-year follow-up study confirms that karyotype is a main prognostic factor for predicting survival. Most particularly, Ph+ ALL were characterized by a poor prognosis with only 10% of long survivors.
Patient populations apparently did not differ significantly over the 21-year period. Nevertheless, the number of patients receiving standard therapy and the median age tended to increase suggesting that populations, considered in analysis 1, were not really compatible. This could be related to the aging
Leukemia
Figure 6
Kaplan-Meier plots of LFS in ALL patients according to immunophenotype. of the population, a possible greater exposure to carcinogens, and certainly a more systematic patient's referring to our hospital. 34 It is likely that they also differed with regard to other, unknown, independent characteristics than would be the case if the 1978-1987 and 1987-1999 populations were identical. Although unknown, these characteristics could be prognostic. It has been shown that known prognostic factors account for only 20-25% of the variability in patient outcome. 35 This raises questions as to the validity of comparison of treatment in these populations and the validity of prognostic factors studied in an ALL population over a long time period. Although both together the improvement of supportive care and the intensification of induction regimens were supposed very likely to improve CR rates and consequently OS, no such results clearly emerged from our data. Induction death rates after one course decreased significantly since 1987. But, when considering the whole ALL cohort, no significant improvement was observed in terms of CR rates and survival. However, our study suggests that better results have been achieved in select subsets of patients over the 21-year period. Most significant improvements have been achieved in the management of T cell lineage ALL patients. These results confirm previous reports 4, 7, 32 and could be attributed to therapeutic modifications including mostly the introduction and/or intensification of cyclophosphamide and cytarabine in standard induction and consolidation therapy, and the intensification of post-remission treatments. 6, 9 Improved outcome also involved other ALL subtypes. Some improvements have also occurred for B-lineage ALL in patients aged less than 60 years since median LFS has increased over the years. However, long-term survival remained unchanged. Although still keeping a very poor prognosis, improvements have indeed been reported in Ph+ ALL outcome (data not shown). 36 This seems related to a better knowledge of this ALL subtype and thus to its more systematic therapeutic intensification by SCT. The classical improved outcome in L3 ALL was not confirmed in our study because of the lack of patients receiving specifically designed regimens. 23 Intensification of post-remission treatment is likely to contribute to improvement of treatment outcome in younger patients. This seems mainly due more to the development of SCT than to the intensification of consolidation chemotherapy. Our retrospective study showed very interesting results in allografted patients when compared to those receiving only chemotherapy, while the benefit of autologous transplant was not evident. In that setting, results of T cell lineage ALL after allografting in first CR were particularly encouraging. Inversely, results of transplantation in further CR were very disappointing. The exact role of allogeneic or autologous transplantation is certainly better assessed by prospective studies with analyses based on the intention-to-treat principle than by retrospective studies. Based on the results of the multicentric LALA-87 trial, stratification by risk groups was proposed for post-remission therapy and applied in further trials. 37, 38 Indeed, while allogeneic BMT was favorable in B cell lineage ALL, results identified the absence of significant difference in intention-to-treat between the allogeneic BMT arm and the no allogeneic BMT arm in T cell lineage ALL. 37, 38 Therefore, only high-risk T cell lineage ALL were allografted after 1994. However, the important discrepancies, observed between previously published results of LALA-87 multicentric prospective trial and those of our present retrospective single center study, make the post-remission strategy in T cell lineage ALL very questionable. Although the multicentric LALA-87 trial was based on an intent-to-treat analysis and involved a large series of patients, the good results observed in our retrospective study on 23 T cell lineage ALL treated by allogeneic BMT as post-remission therapy (74% LFS after 3 years) question the indications of allogeneic BMT in this ALL subtype. The important dispersion in the results of allogeneic BMT in the literature and these apparently contradictory reports are likely to be due to patient selection biases. The difference could be explained by the intent-to-treat method analysis that could bias the results of allogeneic BMT if too many patients randomized in the allogeneic BMT arm did not effectively undergo transplantation. Another explanation could be the high graft-related toxicity observed in some centers. The difference did not seem related to the time-to-transplant effect since time-to-transplant was about the same in both series. 36 In our study, only one patient in four achieved long-term survival. It is noteworthy that most relapses occurred within 3 years of achieving remission. This suggests that a minimum follow-up of 3 years is a reasonable predictor of long-term outcome for adult patients with ALL. However, this seemed really accurate for T cell lineage, while some B and non-B non-T cell lineage ALL continued to relapse until more than 5 years after completing treatment. Over the 21-year period, the percentage of LTS increased modestly. Improvements were probably more as a result of better consolidation or intensification therapy than because of any real change in the CR rate. To our knowledge, none of our LTS developed a subsequent invasive cancer.
Several conclusions can be drawn from our study described herein. First, a significant fraction (23%) of patients achieve long-term survival and seem to be cured of their disease. Relatively few adverse events occur after 3-4 years in remission, and the curves are relatively flat thereafter. These findings have implications regarding the need for and value of expensive and compulsive long-term follow-up of all adult ALL patients treated in clinical trials. However another question arises and cannot be answered by our retrospective study: How well are these patients as citizens of the community? A second conclusion is that during the past decade there have been improvements in the outcome of therapy. These approaches may be of particular benefit to patients with a specific ALL subtype and of little benefit to others. At least in T cell lineage ALL, significant improvements in terms of LFS have been obtained. A remaining challenge is to improve outcomes after remission induction in all other patients. Third, although the sample size is fairly large in this long-term follow-up study, we still cannot be completely confident about the incidence of unusual late, untoward events. We could address the question of whether patients with ALL are at increased risk of secondary cancers. Our data are reassuring since our data suggest that patients in the potentially cured cohort were not particularly at risk of subsequent invasive cancer. This finding contrasts with observations in survivors of other malignancies, who are at greatly increased risk of developing AML. 39 A final conclusion is that the overall data reflect the degree to which ALL treatment remains unsuccessful. Only allogeneic BMT in first CR offered encouraging results.
